MDP Multidose Kit of Technetium Injection
"LA JOLLA, California â€” "If we're going to have this genomics revolution, it's going to be driven by the consumer," Anne Wojcicki, chief executive office and cofounder of 23andMe, said here at the Future of Genomic Medicine IX.
MDP Multidose Kit
MDP Multidose Kit of Technetium Injection Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
MDP Multidose Kit for the Preparation of Technetium Tc99m Medronate Injection is a diagnostic aid used as a bone imaging agent to delineate areas of altered osteogenesis. The brand name of this medication is discontinued, but generic versions may be available. Common side effects include hypersensitivity reactions such as itching, skin rashes, low blood pressure, chills, nausea, and vomiting.
After preparation with oxidant-free sodium pertechnetate Tc99m injection, the suggested dose range of technetium Tc99m medronate injection in the average patient (70 kg) is 370-740 MBq (10-20 mCi) given intravenously. Imaging post injection is optimal at 1 to 4 hours. MDP Multidose Kit may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, MDP Multidose Kit should be used only if prescribed. This drug passes into breast milk. Formula feedings should be substituted for breast feedings. Consult your doctor before breastfeeding.
Our MDP Multidose Kit for the Preparation of Technetium Tc99m Medronate Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
MDP Multidose Kit of Technetium Injection FDA Prescribing Information: Side Effects
Several adverse reactions due to technetium Tc99m medronate have been reported. These were usually hypersensitivity reactions characterized by itching, various skin rashes, hypotension, chills, nausea and vomiting. There have also been rare cases of dizziness and asthenia associated with the use of technetium Tc99m medronate.
The following adverse reactions associated with the use of technetium Tc99m medronate have been identified during post-approval use:
Anaphylactic/anaphylactoid reactions that may be life-threatening and include shock, hypotension, loss of consciousness, dyspnea, cyanosis, and wheezing. Advanced life support equipment and trained personnel should be readily available.
Local or generalized rash with itching and dermal irritation, headache, malaise, edema of the extremities, and arthralgia have also been reported. The time to onset of these symptoms may occur within minutes or be delayed by several hours post-administration of technetium Tc99m medronate. Users are requested to report to GE Healthcare any instances of suspected adverse drug reactions associated with the use of technetium Tc99m medronate.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read the entire FDA prescribing information for MDP Multidose Kit of Technetium Injection (Technetium Tc99m Medronate Injection)
Additional MDP Multidose Kit Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.